{
    "Trade/Device Name(s)": [
        "BD Veritor\u2122 System Flu A + B assay POC kit",
        "BD Veritor\u2122 System for Rapid Detection of Flu A + B"
    ],
    "Submitter Information": "Becton, Dickinson and Company",
    "510(k) Number": "K132259",
    "Predicate Device Reference 510(k) Number(s)": [
        "K112277"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "GNX"
    ],
    "Summary Letter Date": "July 17, 2013",
    "Summary Letter Received Date": "July 19, 2013",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.3330"
    ],
    "Regulation Name(s)": [
        "Influenza virus serological reagents"
    ],
    "Analyte Class(es)": [
        "virology",
        "microbiology",
        "immunology",
        "POCT"
    ],
    "Analyte(s)": [
        "Influenza A viral nucleoprotein antigen",
        "Influenza B viral nucleoprotein antigen"
    ],
    "Specimen Type(s)": [
        "Nasopharyngeal swab",
        "Nasal swab"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "BD Veritor\u2122 System Reader"
    ],
    "Method(s)/Technology(ies)": [
        "Chromatographic immunoassay"
    ],
    "Methodologies": [
        "Immunoassay",
        "Antigen detection"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit",
        "System",
        "Reader"
    ],
    "Document Summary": "FDA 510(k) summary for BD Veritor System Flu A + B rapid chromatographic immunoassay for detection of influenza A and B antigens from respiratory swabs using POCT kit and reader.",
    "Indications for Use Summary": "Aid in diagnosis of influenza A and B viral infections in symptomatic patients by direct, qualitative detection of influenza A and B nucleoprotein antigens from nasopharyngeal and nasal swabs; negative results are presumptive and should be confirmed by viral culture or molecular assay.",
    "fda_folder": "Microbiology"
}